EVA: Evista Alendronate Comparison

The purpose of this study is to determine how treatment with raloxifene compares to treatment with alendronate in postmenopausal women with osteoporosis on the chance of experiencing fractures

The purpose of this study is to determine how treatment with raloxifene compares to treatment with alendronate in postmenopausal women with osteoporosis on the chance of experiencing fractures.Condition:- OsteoporosisStudy Type: InterventionalStudy Design: Treatment Eligibility Ages Eligible for Study: 50 Years – 80 Years, Genders Eligible for Study: Female Criteria Inclusion Criteria50-80 years of age, inclusive 2 years since last menses Dx femoral neck osteoporosis No vertebral fractures Exclusion CriteriaPoor candidate for study drugs Hx of diseases affecting bone metabolism Hx of breast/estrogen-dependent cancer Current use of osteoporosis drug therapy Hx/high risk of VTE [1] Eli Lilly and Company

All content and media on the HealthEngine Blog is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard the advice of a medical professional, or delay in seeking it because of something you have read on this Website. If you think you may have a medical emergency, call your doctor, go to the nearest hospital emergency department, or call the emergency services immediately.